Skip to main content
Premium Trial:

Request an Annual Quote

PathoGenetix Raises $10M in Series C Round

NEW YORK (GenomeWeb News) – PathoGenetix today announced it has secured $10 million in Series C financing to further commercialization efforts for its Genome Sequence Scanning technology.

Participants in the round included existing investors Ascension Health Ventures, Excel Venture Management, and HealthCare Ventures. The funding, PathoGenetix said, will be directed at further development of its first commercial system using the GSS technology, called the Resolution Microbial Genotyping System.

The platform includes the instrument, bioinformatics software and database, as well as pathogen-specific assays. Woburn, Mass.-based PathoGenetix said that it anticipates launching the Resolution System in 2014 for food safety testing applications and foodborne illness outbreak investigations.

GSS is culture independent and fully automated from sample preparation to final report, resulting in a reduction in time, complexity, skill, and cost required for its use, compared to other molecular and next-generation sequencing-based approaches, PathoGenetix said. Additionally, GSS provides strain-type information that is comparable to pulsed field gel electrophoresis, the current standard for pathogen typing in foodborne outbreak investigation and response, it added.

Today's deal follows agreements PathoGenetix announced with the US Food and Drug Administration in April, and the US Department of Agriculture's Agricultural Research Service in September. The same month, it forged a deal with Applied Maths focused on rapid pathogen strain typing. The company today said that it is currently conducting customer evaluations with "leading food safety testing labs."

In 2011 PathoGenetix raised $11.5 million in a Series B round. Earlier this month, the company said in a regulatory document that it raised $3.6 million toward a targeted $9.1 million round. That raise was part of the $10M Series C found, a company spokesman said.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.